With the opening of a new facility in Glasgow, Scotland, toll manufacturer BioOutsource, part of Sartorius Stedim Biotech group, said it has doubled its capacity to support its “robust pipeline” for biotech and biosimilar products currently in development.

The facility is expected to create around 50 new jobs for scientific and technical professionals in the Scottish city over the next six months.  

Thanks to the company’s recent acquisition by Sartorius Stedim Biotech, BioOutsource CEO Gerry MacKay said it expects to become one of the largest employers in this sector in Scotland.  “Further investment in new services is already planned,” he added.  

BioOutsource regards itself as a global leader in biologics contract testing and biosimilar characterisation for the biopharmaceutical industry.